- Global Pharma News & Resources

Treatment-Resistance Depression Treatment Making Advances: Study

Fact.MR ongoing study presents bullish outlook on the treatment-resistance depression treatment market. As per the World Health Organization’s (WHO’s) factsheet, more than 264 million people worldwide of various age groups suffer from depression. Coupled with this, the prevalence of treatment-resistant depression is peaking, especially in America and several countries across Europe.

Treatment-resistant depression (TRD) continues to be one of the highly neglected public health issue. A BMC Psychiatry study has found that treatment resistance is common among patients identified with major depressive disorders. Against this backdrop, the demand for treatment-resistance depression treatment is poised to surge.

While government initiatives towards promoting mental health will remain a chief growth driver, patent-expiry of key antidepressants will create obstacles. Nonetheless, focus on unremitted depression is expected to increase as market players take up various trials and clinical studies. These factors are expected to steer growth in the market.

“Prevalence of stage 1 treatment resistance depression is at 2-3% worldwide, while stage 2 TRD prevalence is estimated to be around 1.5-2%. With the prevalence unlikely to slowdown, effective treatment for the condition is the need of the hour. Thanks to various initiatives undertaken by government and non-government institutions alike, stigma associated with metal health is blurred. In the coming years, the demand for treatment resistance depression treatment is poised to surge,” said a lead analyst at Fact MR.

 Request Free Demo –

Key Takeaways from Fact.MR’s Treatment-resistance Depression Treatment Market Report

  • Demand in North America is expected to rise backed by increasing healthcare spending
  • High prevalence of depression among U.S. adults make the country a lucrative market
  • With diagnoses of mental health issues surging, the U.K. will present conducive environment for growth of the market
  • Lack of awareness and treatment algorithms are restricting expansion in India, nonetheless government initiatives will pave way for growth in future
  • Action plans launched by government departments to focus on child and adolescent mental health are enabling growth in China

Treatment-resistance Depression Treatment Market – Prominent Drivers

  • Increasing prevalence of mental health issues, especially depression and anxiety in adults creating growth opportunities
  • Government initiatives to improve mental health care and make them more accessible will drive growth
  • Increasing prevalence of sedentary lifestyle will contribute to depression, thus enabling growth in the market

Treatment-resistance Depression Treatment Market – Key Restraints

  • Low acceptance of mental disorders might hamper growth in developing countries
  • Patent-expiration of antidepressants emerges as key hurdle for market players

Discover more about the treatment-resistance depression treatment market at-

Competitive Landscape

Some of the leading players operating in the market are AstraZeneca plc, Pfizer, Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, Forest Laboratories (Allergan plc), Janssen Pharmaceuticals, Inc., Schering Plough Corporation, Vistagen Therapeutics, Inc., Wyeth and others.

Maximum number of companies in the market will continue focusing on developing newer and more effective drugs. Besides this, inorganic strategies including merger and acquisition and strategic collaborations will remain highly sought-after among the market players.

More Insights into Treatment-resistance Depression Treatment Market

In its latest report, Fact.MR offers unbiased analysis of the global treatment-resistance depression treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of drug class (tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs)), serotonin norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), serotonin neurotransmitter (5-HT2)-receptor antagonists, and novel agents), application (depression, anxiety, mental disorder), and end user (mental hospitals and psychiatric clinics) across seven regions (North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific excluding Japan, and Middle East & Africa)

Request more information about Report Customization

Explore Fact.MR’s Coverage on the Healthcare Domain

Nano Healthcare Technology Market: A recent study by Fact.MR on the nano healthcare technology market offers a 10-year forecast. The study analyzes crucial trends that are currently determining the growth of the nano healthcare technology market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders.

Paper Diagnostics Market: A recent study by Fact.MR on the paper diagnostics market analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders and emerging players associated with the manufacturing of paper diagnostics.

Monopolar Electrosurgery Market: The monopolar electrosurgery study analyzes crucial trends currently determining the market growth. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players and emerging players associated with the production of monopolar electrosurgery products.

About us:

A differentiated market research and consulting agency! That’s why 80% of Fortune 1000 companies trust us to make the most important decisions. Our seasoned consultants use the latest technology to create hard-to-find insights, but USP believes in our clients’ trust in our expertise. Coverage spans a wide range from automotive and Industry 4.0 to healthcare and retail, but most niche categories can also be analyzed. We have sales offices in the US and Dublin, Ireland. It is headquartered in Dubai, United Arab Emirates. Tell us your goals and we will become a competent research partner.


US Office:
11140 Rockville Hecht Suite 400
Rockville, MD 20852
Tel: +1 (628) 251-1583

Unit number: AU-01-H Gold Tower (AU),
Lot number: JLT-PH1-I3A,
Jumeirah Lakes Tower,
Dubai, United Arab Emirates
Homepage:  https: //

The post Treatment-Resistance Depression Treatment Making Advances: Study appeared first on Latest Market Reports.

Editor Details

Last Updated: 01-Oct-2021